Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New epilepsy drug SPN-817 tested for Long-Term safety in adults

NCT ID NCT07141329

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times

Summary

This study looks at the long-term safety and effectiveness of an investigational drug called SPN-817 for adults with focal onset seizures. About 100 people who completed a previous SPN-817 study will take the drug for one year. Researchers will track side effects and changes in seizure frequency.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL ONSET SEIZURES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medsol Clinical Research Center

    RECRUITING

    Port Charlotte, Florida, 33952, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.